Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTLicense, Development and Commercialization Agreement • October 3rd, 2019 • Aridis Pharmaceuticals, Inc. • Pharmaceutical preparations • California
This LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”) is entered into as of September 27th, 2019 (the “Effective Date”) by and between ARIDIS PHARMACEUTICALS, INC., a corporation organized and existing under the laws of Delaware, U.S.A., and having a principal place of business at 5941 Optical Court, San Jose, CA 95138, U.S.A. (“Aridis”), and SERUM AMR PRODUCTS , a Netherlands based company having a place of business at Antonie van Leeuwenhoeklaan 9-13, 3721 AL Bilthoven, PO Box 457, The Netherlands (“SAMR”). Aridis and SAMR are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
